###begin article-title 0
Activation of Peroxisome Proliferator-Activated Receptor beta/delta Inhibits Lipopolysaccharide-Induced Cytokine Production in Adipocytes by Lowering Nuclear Factor-kappaB Activity via Extracellular Signal-Related Kinase 1/2
###end article-title 0
###begin p 1
###xml 46 68 46 68 <email xmlns:xlink="http://www.w3.org/1999/xlink">mvazquezcarrera@ub.edu</email>
Corresponding author: Manuel Vazquez-Carrera, mvazquezcarrera@ub.edu
###end p 1
###begin p 2
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See  for details.
###end p 2
###begin p 3
###xml 0 10 0 10 <bold xmlns:xlink="http://www.w3.org/1999/xlink">OBJECTIVE&#8212;</bold>
OBJECTIVE-Chronic activation of the nuclear factor-kappaB (NF-kappaB) in white adipose tissue leads to increased production of pro-inflammatory cytokines, which are involved in the development of insulin resistance. It is presently unknown whether peroxisome proliferator-activated receptor (PPAR) beta/delta activation prevents inflammation in adipocytes.
###end p 3
###begin p 4
###xml 0 40 0 40 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESEARCH DESIGN AND METHODS AND RESULTS&#8212;</bold>
###xml 621 625 <span type="species:ncbi:10116">rats</span>
###xml 654 658 <span type="species:ncbi:10116">rats</span>
###xml 942 946 <span type="species:ncbi:10090">mice</span>
###xml 965 969 <span type="species:ncbi:10090">mice</span>
###xml 1399 1403 <span type="species:ncbi:10116">rats</span>
###xml 1428 1432 <span type="species:ncbi:10090">mice</span>
RESEARCH DESIGN AND METHODS AND RESULTS-First, we examined whether the PPARbeta/delta agonist GW501516 prevents lipopolysaccharide (LPS)-induced cytokine production in differentiated 3T3-L1 adipocytes. Treatment with GW501516 blocked LPS-induced IL-6 expression and secretion by adipocytes and the subsequent activation of the signal transducer and activator of transcription 3 (STAT3)-Suppressor of cytokine signaling 3 (SOCS3) pathway. This effect was associated with the capacity of GW501516 to impede LPS-induced NF-kappaB activation. Second, in in vivo studies, white adipose tissue from Zucker diabetic fatty (ZDF) rats, compared with that of lean rats, showed reduced PPARbeta/delta expression and PPAR DNA-binding activity, which was accompanied by enhanced IL-6 expression and NF-kappaB DNA-binding activity. Furthermore, IL-6 expression and NF-kappaB DNA-binding activity was higher in white adipose tissue from PPARbeta/delta-null mice than in wild-type mice. Because mitogen-activated protein kinase-extracellular signal-related kinase (ERK)1/2 (MEK1/2) is involved in LPS-induced NF-kappaB activation in adipocytes, we explored whether PPARbeta/delta prevented NF-kappaB activation by inhibiting this pathway. Interestingly, GW501516 prevented ERK1/2 phosphorylation by LPS. Furthermore, white adipose tissue from animal showing constitutively increased NF-kappaB activity, such as ZDF rats and PPARbeta/delta-null mice, also showed enhanced phospho-ERK1/2 levels.
###end p 4
###begin p 5
###xml 0 12 0 12 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CONCLUSIONS&#8212;</bold>
CONCLUSIONS-These findings indicate that activation of PPARbeta/delta inhibits enhanced cytokine production in adipocytes by preventing NF-kappaB activation via ERK1/2, an effect that may help prevent insulin resistance.
###end p 5
###begin p 6
Published ahead of print at  on 28 April 2008.
###end p 6
###begin p 7
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
###end p 7
###begin p 8
###xml 222 223 222 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 484 485 476 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r2">2</xref>
###xml 486 487 478 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 585 586 577 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r5">5</xref>
###xml 587 588 579 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r7">7</xref>
###xml 723 724 715 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r6">6</xref>
###xml 987 988 971 972 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 1326 1327 1310 1311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
###xml 1902 1903 1878 1879 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 644 652 <span type="species:ncbi:9606">patients</span>
###xml 1205 1210 <span type="species:ncbi:9606">human</span>
Accumulating evidence implicates a low-grade chronic systemic inflammatory response to nutrient excess as a key mechanism that links obesity to metabolic disorders, including insulin resistance and cardiovascular disease (1). Thus, models of diet-induced and genetic obesity show increased adipose tissue expression and content of pro-inflammatory cytokines (such as tumor necrosis factor-alpha [TNF-alpha], interleukin [IL] 1, monocyte chemo-attractant protein-1 [MCP-1], and IL-6) (2-4). Of these cytokines, IL-6 correlates most strongly with insulin resistance and type 2 diabetes (5-7); its plasma levels are increased two- to threefold in patients with obesity and type 2 diabetes compared with lean control subjects (6). At the cellular level, insulin resistance and enhanced expression of these cytokines by adipose tissue during obesity and also under a high-fat diet have been linked to activation of the pro-inflammatory transcription factor nuclear factor-kappaB (NF-kappaB) (4). This nuclear factor is activated by surface proteins that recognize foreign substances, the so-called pattern recognition receptors, such as toll-like receptor-4 (TLR4). This receptor is expressed on virtually all human cells and binds a wide spectrum of exogenous and endogenous ligands, including bacterial lipopolysaccharide (LPS) (8). In the presence of LPS, the TLR4 complex (including CD-14 and an accessory protein, MD-2), recruits the adaptor protein, myeloid differentiation factor-88, which in turn recruits IL-1 receptor-associated kinase, leading to NF-kappaB activation and enhanced expression of several inflammatory mediators (including IL-6 and MCP-1). Of note, NF-kappaB activation by LPS requires mitogen-activated protein kinase (MAPK)-extracellular signal-related kinase (ERK)1/2 (MEK1/2) activation, because inhibition of this pathway reduces LPS-induced cytokine production in adipocytes (9).
###end p 8
###begin p 9
###xml 156 158 156 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r10">10</xref>
###xml 346 348 346 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r10">10</xref>
###xml 522 524 522 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 694 696 694 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r12">12</xref>
###xml 913 915 913 915 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r12">12</xref>
###xml 733 737 <span type="species:ncbi:10090">mice</span>
Recent evidence suggests that inflammatory processes induced by obesity and high-fat diet cause systemic insulin resistance via a mechanism involving TLR4 (10). For instance, saturated free fatty acids (FFAs) activate TLR4-mediated inflammatory signaling in adipocytes and macrophages, and this effect is blunted in the absence of this receptor (10). These observations indicate that enhanced adipose tissue lipolysis observed in insulin-resistant states may release the endogenous ligand for TLR4 to induce inflammation (11). In addition, it has been demonstrated that high-fat diets augment plasma LPS to a concentration sufficient to increase body weight, fasting glycemia and inflammation (12). Furthermore, LPS receptor-deleted mice (CD14 mutants) are hypersensitive to insulin, and the development of insulin resistance, obesity, and diabetes in this animal model is delayed in response to a high-fat diet (12).
###end p 9
###begin p 10
###xml 166 168 152 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
###xml 435 437 421 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
###xml 863 865 849 851 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r15">15</xref>
###xml 866 868 852 854 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18">18</xref>
###xml 935 937 917 919 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r19">19</xref>
###xml 1284 1286 1255 1257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
###xml 2239 2240 2148 2149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 1874 1877 <span type="species:ncbi:10116">rat</span>
###xml 2144 2148 <span type="species:ncbi:10090">mice</span>
###xml 2167 2171 <span type="species:ncbi:10090">mice</span>
###xml 2518 2521 <span type="species:ncbi:10116">rat</span>
###xml 2550 2554 <span type="species:ncbi:10090">mice</span>
In recent years, peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) activation has been proposed as a potential treatment for insulin resistance (13). PPARs are members of the nuclear receptor superfamily of ligand-inducible transcription factors. They form heterodimers with retinoid X receptors (RXRs) and bind to consensus DNA sites composed of direct repeats of hexameric DNA sequences separated by 1 bp (DR1) (14). Ligand binding induces a conformational change in PPAR-RXR complexes, thereby releasing corepressors in exchange for coactivators, which leads to the recruitment of the basal transcription machinery and enhanced gene expression. In addition, PPARs may suppress inflammation through diverse mechanisms, such as reduced release of inflammatory factors or stabilization of repressive complexes at inflammatory gene promoters (15-18). Of the three PPAR isotypes found in mammals, PPARalpha (NR1C1) (19) and PPARgamma (NR1C3) are the targets for hypolipidemic (fibrates) and antidiabetic (thiazolidinediones) drugs, respectively. Finally, activation of the third isotype, PPARbeta/delta (NR1C2) by high-affinity ligands (including GW501516) enhances fatty acid catabolism in adipose tissue and skeletal muscle, thereby delaying weight gain (rev. in 13). However, there is no information available on whether PPARbeta/delta ligands prevent inflammation in adipocytes. Here, we examined whether PPARbeta/delta activation by GW501516 prevents LPS-induced inflammation in adipocytes. We found that this drug prevented LPS-induced IL-6 expression and secretion by adipocytes. This effect was associated with the capacity of the PPARbeta/delta ligand to prevent LPS-induced NF-kappaB activation. Consistent with the role of PPARbeta/delta in blocking NF-kappaB-induced IL-6 expression, a genetic model of obesity and insulin resistance, the ZDF rat, showed reduced PPARbeta/delta expression and DNA-binding activity and enhanced IL-6 expression and NF-kappaB DNA-binding activity in white adipose tissue. Likewise, IL-6 expression and NF-kappaB DNA-binding activity was higher in this tissue in PPARbeta/delta-null mice than in wild-type mice. Because MEK1/2 is involved in NF-kappaB activation in adipocytes (9), we explored whether PPARbeta/delta blocked NF-kappaB activation by inhibiting this pathway. In agreement with this possibility, GW501516 prevented ERK1/2 phosphorylation by LPS. In contrast, animal models showing increased NF-kappaB activity in white adipose tissue, the ZDF rat and the PPARbeta/delta-null mice, showed enhanced phospho-ERK1/2 levels. Overall, on the basis of our findings, we propose that PPARbeta/delta activation be considered a molecular target to prevent inflammation of adipose tissue and the metabolic alterations associated with this process, such as insulin resistance.
###end p 10
###begin title 11
RESEARCH DESIGN AND METHODS
###end title 11
###begin p 12
The PPARbeta/delta ligand GW501516 was from Biomol Research Labs (Plymouth Meeting, PA). Other chemicals were from Sigma (St. Louis, MO).
###end p 12
###begin title 13
Cell culture.
###end title 13
###begin p 14
###xml 148 154 <span type="species:ncbi:9913">bovine</span>
###xml 155 159 <span type="species:ncbi:9913">calf</span>
###xml 276 282 <span type="species:ncbi:9913">bovine</span>
3T3-L1 preadipocytes (American Type Culture Collection) were grown to confluence in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% bovine calf serum. Differentiation of the 3T3-L1 cells was induced 2 days after confluence (day 0) in DMEM containing 10% fetal bovine serum, 500 mumol/l methylisobutylxanthine, 0.25 mumol/l dexamethasone, and 10 mug/ml insulin for 48 h. The cells were then incubated in 10% FBS/DMEM with insulin for 8 days. Medium was changed every 2 days. Fat droplets were observed in >90% of cells after day 10. Adipocytes were then incubated for 96 h with 0.5 mumol/l GW501516 and then with 100 ng/ml LPS for either 1 or 24 h. After the incubation, RNA, total proteins, and nuclear extracts were extracted from adipocytes as described below. Inhibitors were added 30 min before the incubation with LPS. Culture supernatants were collected, and the secretion of IL-6 was assessed by ELISA (Amersham Biosciences, Little Chalfont, U.K.).
###end p 14
###begin title 15
Animals.
###end title 15
###begin p 16
###xml 30 35 30 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">fa/fa</italic>
###xml 60 64 60 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">fa/+</italic>
###xml 68 71 68 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">+/+</italic>
###xml 443 444 429 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
###xml 972 974 945 947 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r20">20</xref>
###xml 15 19 <span type="species:ncbi:10116">rats</span>
###xml 936 940 <span type="species:ncbi:10090">mice</span>
Male obese ZDF rats (ZDF/Gmi, fa/fa) and lean litter mates (fa/+ or +/+) were used. Both strains were maintained under standard light-dark cycle (12-h light/dark cycle) and temperature (21 +/- 1degreesC) and fed with the Purina 5008 chow. Epidydimal white adipose tissue was rapidly removed, frozen in liquid nitrogen, and stored at -80degreesC. Blood samples were collected in EDTA tubes, and plasma was obtained by centrifugation at 2,200 x g for 10 min at 4degreesC. Plasma glucose (Sigma), triglycerides (Sigma), and nonesterified fatty acids (Wako, Germany) levels were determined with a colorimetric test. Insulin (Amersham Biosciences) was determined by radioimmunoassay. All procedures were conducted in accordance with the principles and guidelines established by the University of Barcelona Bioethics Committee, as stated in Law 5/1995, 21st July, passed by the Generalitat de Catalunya. The generation of PPARbeta/delta-null mice has been described previously (20).
###end p 16
###begin title 17
Measurements of mRNA.
###end title 17
###begin p 18
###xml 68 70 68 70 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r21">21</xref>
###xml 322 326 322 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-6</italic>
###xml 389 394 389 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mcp-1</italic>
###xml 457 462 457 462 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdk-4</italic>
###xml 525 530 525 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cpt-I</italic>
###xml 593 602 593 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ppar&#946;/</italic>
###xml 669 675 662 668 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Socs-3</italic>
###xml 779 783 772 776 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Aprt</italic>
###xml 918 922 911 915 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-6</italic>
###xml 932 937 925 930 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mcp-1</italic>
###xml 939 942 932 935 <italic xmlns:xlink="http://www.w3.org/1999/xlink">157</italic>
###xml 947 952 940 945 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdk-4</italic>
###xml 954 957 947 950 <italic xmlns:xlink="http://www.w3.org/1999/xlink">167</italic>
###xml 962 967 955 960 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cpt-I</italic>
###xml 969 972 962 965 <italic xmlns:xlink="http://www.w3.org/1999/xlink">222</italic>
###xml 977 986 970 976 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ppar&#946;/</italic>
###xml 1001 1007 987 993 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Socs-3</italic>
###xml 1021 1025 1007 1011 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Aprt</italic>
###xml 1313 1315 1299 1301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r22">22</xref>
###xml 1529 1533 1515 1519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Aprt</italic>
Levels of mRNA were assessed by the RT-PCR as previously described (21). Total RNA was isolated using the Ultraspec reagent (Biotecx, Houston, TX). The total RNA isolated by this method is nondegraded and free of protein and DNA contamination. The sequences of the sense and antisense primers used for amplification were: IL-6, 5'-TCCAGCCAGTTGCCTTCTTGG-3' and 5'-TCTGACAGTGCATCATCGCTG-3'; Mcp-1, 5'-GGGCCTGTTGTTCACAGTTGC-3' and 5'-GGGACACCTGCTGCTGGTGAT-3'; Pdk-4, 5'-AGGTCGAGCTGTTCTCCCGCT-3' and 5'-GCGGTCAGGCAGGATGTCAAT-3'; Cpt-I, 5'-TTCACTGTGACCCCAGACGGG-3' and 5'-AATGGACCAGCCCCATGGAGA-3'; Pparbeta/delta 5'-GAGGAAGTGGCCACGGGTGAC-3' and 5'-CCACCTGAGGCCCCATCACAG-3'; Socs-3, 5'-TTTTCGCTGCAGAGTGACCCC-3' and 5'-TGGAGGAGAGAGGTCGGCTCA-3'; and adenosyl phosphoribosyl transferase (Aprt), 5'-GCCTCTTGGCCAGTCACCTGA-3' and 5'-CCAGGCTCACACACTCCACCA-3'. Amplification of each gene yielded a single band of the expected size (IL-6, 229 bp; Mcp-1, 157 bp; Pdk-4, 167 bp; Cpt-I, 222 bp; Pparbeta/delta, 151 bp; Socs-3, 250 bp; and Aprt, 329 bp). Preliminary experiments were carried out with various amounts of cDNA to determine nonsaturating conditions of PCR amplification for all the genes studied. Therefore, under these conditions, relative quantification of mRNA was assessed by the RT-PCR method used in this study (22). Radioactive bands were quantified by video-densitometric scanning (Vilbert Lourmat imaging). The results for the expression of specific mRNAs are always presented relative to the expression of the control gene (Aprt).
###end p 18
###begin title 19
Isolation of nuclear extracts.
###end title 19
###begin p 20
###xml 56 58 56 58 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r21">21</xref>
###xml 217 218 210 211 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 660 661 645 646 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Nuclear extracts were isolated as previously described (21). Cells were scraped into 1.5 ml cold PBS, pelleted for 10 s, and resuspended in 400 mul cold buffer A (10 mmol/l HEPES, pH 7.9, at 4degreesC, 1.5 mmol/l MgCl2, 10 mmol/l KCl, 0.5 mmol/l dithiothreitol [DTT], 0.2 mmol/l phenylmethylsulfonyl fluoride [PMSF], and 5 mug/ml aprotinin) by flicking the tube. Cells were allowed to swell on ice for 10 min and then vortexed for 10 s. Samples were then centrifuged for 10 s, and the supernatant fraction was discarded. Pellets were resuspended in 50 mul cold buffer C (20 mmol/l HEPES-KOH, pH 7.9, at 4degreesC, 25% glycerol, 420 mmol/l NaCl, 1.5 mmol/l MgCl2, 0.2 mmol/l EDTA, 0.5 mmol/l DTT, 0.2 mmol/l PMSF, 5 mug/ml aprotinin, and 2 mug/ml leupeptin) and incubated on ice for 20 min for high-salt extraction. Cellular debris was removed by centrifugation for 2 min at 4degreesC and the supernatant fraction (containing DNA-binding proteins) was stored at -80degreesC. Nuclear extract concentration was determined by the Bradford method.
###end p 20
###begin title 21
Electrophoretic mobility shift assay.
###end title 21
###begin p 22
###xml 435 437 421 423 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
Electrophoretic mobility shift assay (EMSA) was performed using double-stranded oligonucleotides (Promega, Madison, WI) for the consensus binding site of the NF-kappaB nucleotide (5'-AGTTGAGGGGACTTTCCCAGGC-3') and PPAR (5'-CAAAACTAGGTCAAAGGTCA-3'). Oligonucleotides were labeled in the following reaction: 2 mul oligonucleotide (1.75 pmol/mul), 2 mul 5x kinase buffer, 1 mul T4 polynucleotide kinase (10 units/mul), and 2.5 mul [gamma-32P]ATP (3,000 Ci/mmol at 10 mCi/ml) incubated at 37degreesC for 1 h. The reaction was stopped by adding 90 mul Tris-EDTA buffer (10 mmol/l Tris-HCl, pH 7.4, and 1 mmol/l EDTA). To separate the labeled probe from the unbound ATP, the reaction mixture was eluted in a Nick column (Amersham) following the manufacturer's instructions. Eight micrograms of crude nuclear protein was incubated for 10 min on ice in binding buffer (10 mmol/l Tris-HCl, pH 8.0, 25 mmol/l KCl, 0.5 mmol/l DTT, 0.1 mmol/l EDTA, pH 8.0, 5% glycerol, 5 mg/ml BSA, and 50 mug/ml poly(dI-dC)), in a final volume of 15 mul. Labeled probe (approximately60,000 cpm) was added, and the reaction was incubated for 15 min at 4degreesC (NF-kappaB) or room temperature (peroxisome proliferator response element). Where indicated, specific competitor oligonucleotide was added before the labeled probe and incubated for 10 min on ice. p65 antibody was added 15 min before incubation with the labeled probe at 4degreesC. Protein-DNA complexes were resolved by electrophoresis at 4degreesC on a 5% acrylamide gel and subjected to autoradiography.
###end p 22
###begin title 23
Immunoblotting.
###end title 23
###begin p 24
###xml 249 250 248 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
###xml 641 644 633 636 <sup xmlns:xlink="http://www.w3.org/1999/xlink">705</sup>
###xml 653 656 645 648 <sup xmlns:xlink="http://www.w3.org/1999/xlink">727</sup>
To obtain total protein, cells and adipose tissue were homogenized in cold lysis buffer (5 mmol/l Tris-HCl, pH 7.4, 1 mmol/l EDTA, 0.1 mmol/l PMSF, 1 mmol/l sodium orthovanadate, and 5.4 mug/ml aprotinin). The homogenate was centrifuged at 16,700 x g for 30 min at 4degreesC. Protein concentration was measured by the Bradford method. Proteins (30 mug) were resolved by SDS-PAGE on 10% separation gels and transferred to Immobilon polyvinylidene difluoride membranes (Millipore, Bedford, MA). Western blot analysis was performed using antibodies against total and phospho-ERK1/2 (Cell Signaling) and total (Santa Cruz) and phospho-STAT3 (Tyr705) and Ser727) (Cell Signaling). Detection was achieved using the EZ-ECL chemiluminescence kit (Amersham). Size of detected proteins was estimated using protein molecular-mass standards (Invitrogen, Barcelona, Spain).
###end p 24
###begin title 25
Statistical analyses.
###end title 25
###begin p 26
###xml 122 123 120 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 427 428 425 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Results are expressed as means +/- SD of five separate experiments. Significant differences were established by Student's t test or one-way ANOVA, according to the number of groups compared, using the GraphPad Instat program, v2.03 (GraphPad Software, San Diego, CA). In the latter case, when significant variations were found, the Tukey-Kramer multiple comparisons test was applied. Differences were considered significant at P < 0.05.
###end p 26
###begin title 27
RESULTS
###end title 27
###begin title 28
PPARbeta/delta activation prevents LPS-induced IL-6 expression and secretion in 3T3-L1 adipocytes.
###end title 28
###begin p 29
###xml 135 136 127 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 136 137 128 129 <sub xmlns:xlink="http://www.w3.org/1999/xlink">d</sub>
###xml 202 203 191 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">/</italic>
###xml 239 241 216 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r23">23</xref>
###xml 376 380 346 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdk4</italic>
###xml 420 425 390 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cpt-I</italic>
###xml 428 430 398 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r24">24</xref>
###xml 511 515 481 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdk4</italic>
###xml 523 524 493 494 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 537 542 507 512 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cpt-I</italic>
###xml 549 550 519 520 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 566 567 536 537 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 560 567 530 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>A</italic></xref>
###xml 695 699 664 668 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdk4</italic>
###xml 707 708 676 677 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 722 727 691 696 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cpt-I</italic>
###xml 735 736 704 705 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 752 753 721 722 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 746 753 715 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>B</italic></xref>
###xml 947 949 905 907 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ob</italic>
###xml 1342 1343 1289 1290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 1344 1346 1291 1293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r25">25</xref>
###xml 1380 1382 1327 1329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r12">12</xref>
###xml 1383 1385 1330 1332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r26">26</xref>
###xml 1425 1430 1372 1377 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mcp-1</italic>
###xml 1615 1616 1558 1559 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1715 1716 1658 1659 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1754 1755 1697 1698 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 1748 1755 1691 1698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>A</italic></xref>
###xml 1899 1901 1837 1839 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r27">27</xref>
###xml 2016 2017 1954 1955 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 2109 2110 2047 2048 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 2103 2110 2041 2048 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>B</italic></xref>
###xml 2294 2295 2228 2229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 2288 2295 2222 2229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>C</italic></xref>
###xml 2349 2350 2283 2284 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 2393 2394 2327 2328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 2502 2508 2436 2442 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Socs-3</italic>
###xml 2535 2537 2469 2471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r28">28</xref>
###xml 2598 2600 2532 2534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r29">29</xref>
###xml 2640 2646 2574 2580 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Socs-3</italic>
###xml 2697 2698 2631 2632 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 2703 2704 2637 2638 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 2691 2704 2625 2638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>D</italic> and <italic>E</italic></xref>
###xml 2800 2802 2734 2736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r30">30</xref>
Differentiated 3T3-L1 adipocytes were exposed for 24 h to 0.5 mumol/l GW501516, a selective ligand for PPARbeta/delta with an apparent Kd value of 1 nmol/l and 1,000-fold higher affinity toward PPARbeta/delta than PPARalpha and PPARgamma (23). Under these conditions, we evaluated the expression of two well-known PPARbeta/delta-target genes, pyruvate dehydrogenase kinase 4 (Pdk4) and carnitine palmitoyltransferase 1 (Cpt-I) (24). Ligand treatment for 24 h caused a slight increase in the mRNA levels of both Pdk4 (100%, P < 0.01) and Cpt-I (45%, P < 0.05) (Fig. 1A). When adipocytes were treated for 96 h with 0.5 mumol/l GW501516, a greater increase was observed in the transcript levels of Pdk4 (170%, P < 0.001) and Cpt-I (300%, P < 0.01) (Fig. 1B). Therefore, we selected this longer exposure to the PPARbeta/delta ligand in further experiments. No changes were observed either in the expression of well-known PPARgamma-target genes (i.e., Ob: data not shown), confirming that the drug treatment was selective for PPARbeta/delta, or in the expression of markers of adipocyte differentiation (i.e., Pref-1; data not shown), indicating that this latter process was unaffected. After a 96 h-incubation with GW501516, cells were exposed to 100 ng/ml LPS for 24 h to induce inflammation. LPS activates NF-kappaB through TLRs in adipocytes (9,25) and induces insulin resistance (12,26). When we evaluated the mRNA levels of Mcp-1 and IL-6, two genes that are under the control of the pro-inflammatory transcription factor NF-kappaB, we observed that LPS treatment strongly increased the former (22-fold induction, P < 0.001), whereas cells co-incubated with GW501516 showed a significant reduction (51% reduction, P < 0.01 vs. LPS-exposed cells) (Fig. 2A). Furthermore, when LPS-exposed cells were co-incubated with 10 mumol/l parthenolide, which specifically inhibits the activation of NF-kappaB (27), the effect of LPS was suppressed. Treatment with LPS also led to enhanced IL-6 mRNA levels (4.2-fold induction, P < 0.05), but this increase was blocked in the presence of GW501516 and parthenolide (Fig. 2B). Likewise, incubation with LPS for 24 h caused a 4.2-fold increase in the levels of IL-6 protein secreted into the culture media (control 10.5 +/- 3.7 vs. LPS 55 +/- 11 ng/ml; Fig. 2C), whereas pretreatment with GW501516 (56% reduction, P < 0.001) and parthenolide (32% reduction, P < 0.05) significantly reduced the secretion of this cytokine. Several cytokines, including IL-6, stimulate Socs-3 expression in adipocytes (28), a protein that inhibits insulin signaling in these cells (29). The elevated levels of mRNA encoding Socs-3 and the increase in Stat-3 phosphorylation (Fig. 2D and E) suggested that the increase in IL-6 release caused by LPS treatment might have local actions (30). Interestingly, GW501516 treatment prevented the increase in Socs-3 expression and Stat-3 phosphorylation, a fact that is consistent with the reduction in IL-6 levels after drug treatment.
###end p 29
###begin title 30
PPARbeta/delta activation prevents LPS-mediated NF-kappaB activation in 3T3-L1 adipocytes.
###end title 30
###begin p 31
###xml 321 322 309 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 315 322 303 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>A</italic></xref>
###xml 595 596 575 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 589 596 569 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>B</italic></xref>
###xml 719 720 688 689 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 713 720 682 689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>A</italic></xref>
###xml 888 889 853 854 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 882 889 847 854 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>C</italic></xref>
Activation of NF-kappaB plays a crucial role in IL-6 production in adipocytes, as demonstrated by the effects of parthenolide. To test whether GW501516 prevented LPS-induced IL-6 expression by reducing NF-kappaB activity, we performed EMSA. NF-kappaB formed three complexes with nuclear proteins (complexes I-III) (Fig. 3A). The specificity of the three DNA-binding complexes was assessed in competition experiments by adding an excess of unlabeled NF-kappaB oligonucleotide. NF-kappaB binding activity, mainly of specific complex II, increased in nuclear extracts from LPS-treated cells (Fig. 3B). In contrast, in the presence of LPS and the PPARbeta/delta ligand, the binding activity of NF-kappaB was reduced (Fig. 3A). Addition of antibody against the p65 subunit of NF-kappaB completely supershifted complex II, thereby indicating that this band comprised mainly this subunit (Fig. 3C).
###end p 31
###begin title 32
Reduced PPARbeta/delta activity and enhanced IL-6 expression in white adipose tissue of an animal model of obesity and insulin resistance.
###end title 32
###begin p 33
###xml 377 382 359 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink">fa/fa</italic>
###xml 614 615 592 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 675 676 649 650 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 752 753 722 723 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 813 814 779 780 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 891 900 857 863 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ppar&#946;/</italic>
###xml 934 935 893 894 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 951 952 910 911 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 945 952 904 911 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>A</italic></xref>
###xml 1002 1006 961 965 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdk4</italic>
###xml 1032 1033 991 992 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1049 1050 1008 1009 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1043 1050 1002 1009 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>B</italic></xref>
###xml 1185 1186 1144 1145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1202 1203 1161 1162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1196 1203 1155 1162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>C</italic></xref>
###xml 1340 1341 1299 1300 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1334 1341 1293 1300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>D</italic></xref>
###xml 1448 1449 1403 1404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1442 1449 1397 1404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>E</italic></xref>
###xml 384 388 <span type="species:ncbi:10116">rats</span>
###xml 408 412 <span type="species:ncbi:10116">rats</span>
###xml 462 466 <span type="species:ncbi:10116">rats</span>
###xml 852 856 <span type="species:ncbi:10116">rats</span>
###xml 1301 1305 <span type="species:ncbi:10116">rats</span>
###xml 1409 1413 <span type="species:ncbi:10116">rats</span>
We hypothesized that a reduction in PPARbeta/delta activity and the consequent increase in NF-kappaB activity is responsible, at least in part, for the enhanced expression of IL-6 in white adipose tissue of animal models of obesity and insulin resistance. To check this hypothesis, we evaluated the expression of PPARbeta/delta and its activity in white adipose tissue of ZDF (fa/fa) rats. Male ZDF and lean rats were killed at 12 weeks of age. By this age, ZDF rats presented established diabetes compared with lean animals, as demonstrated by increased plasma levels of glucose (505 +/- 67 vs. 167 +/- 37 mg/dl, P < 0.0001), triglycerides (649 +/- 298 vs. 92 +/- 31 mg/dl, P < 0.01), nonesterified fatty acids (0.62 +/- 0.17 vs. 0.26 +/- 0.09 mEq/l, P < 0.01), and insulin (19.3 +/- 7.9 vs. 10.4 +/- 2.0 ng/ml, P < 0.05). White adipose tissue of ZDF rats showed a significant reduction in Pparbeta/delta transcripts (50% reduction, P < 0.05) (Fig. 4A). Similarly, the mRNA levels of its target gene, Pdk4, were also reduced (41%, P < 0.05) (Fig. 4B), suggesting that the activity of this PPAR isotype was reduced. In contrast, the expression of IL-6 was significantly enhanced (60%, P < 0.05) (Fig. 4C). EMSA showed that the DNA-binding activity of PPAR was reduced in white adipose tissue from ZDF rats compared with lean animals (Fig. 4D). In contrast, NF-kappaB DNA-binding activity was increased in ZDF rats compared with lean animals (Fig. 4E). These data suggest that the low-grade chronic systemic inflammatory associated with the development of obesity and insulin resistance involves a decreased PPARbeta/delta activity and the subsequent activation of NF-kappaB.
###end p 33
###begin p 34
###xml 94 98 83 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Il-6</italic>
###xml 188 197 170 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ppar&#946;/</italic>
###xml 234 235 209 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 228 235 203 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>A</italic></xref>
###xml 291 295 266 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdk4</italic>
###xml 302 303 277 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 320 321 295 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 314 321 289 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>B</italic></xref>
###xml 411 412 386 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 428 429 403 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 422 429 397 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>C</italic></xref>
###xml 632 633 596 597 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 626 633 590 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>D</italic></xref>
###xml 167 171 <span type="species:ncbi:10090">mice</span>
###xml 347 351 <span type="species:ncbi:10090">mice</span>
###xml 529 533 <span type="species:ncbi:10090">mice</span>
###xml 620 624 <span type="species:ncbi:10090">mice</span>
To clearly demonstrate the involvement of PPARbeta/delta in the control of NF-kappaB-mediated Il-6 expression in white adipose tissue, we used the PPARbeta/delta-null mice. The absence of Pparbeta/delta in white adipose tissue (Fig. 5A) was associated with a reduction in the mRNA levels of Pdk4 (65%, P < 0.001) (Fig. 5B) compared with wild-type mice, whereas IL-6 expression was enhanced (fourfold induction, P < 0.05) (Fig. 5C). In agreement with the enhanced expression of IL-6 in white adipose tissue of PPARbeta/delta-null mice, NF-kappaB binding activity was higher in this tissue compared with that of wild-type mice (Fig. 5D).
###end p 34
###begin title 35
PPARbeta/delta regulates ERK1/2 phosphorylation in adipocytes.
###end title 35
###begin p 36
###xml 307 309 269 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r31">31</xref>
###xml 514 515 468 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 687 688 641 642 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 681 688 635 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6<italic>A</italic></xref>
###xml 1098 1103 1044 1049 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mcp-1</italic>
###xml 1124 1125 1070 1071 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1165 1166 1111 1112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1223 1224 1169 1170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1243 1244 1189 1190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1333 1334 1279 1280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1339 1340 1285 1286 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1327 1340 1273 1286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6<italic>B</italic> and <italic>C</italic></xref>
###xml 1437 1438 1383 1384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1431 1438 1377 1384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6<italic>D</italic></xref>
###xml 579 583 <span type="species:ncbi:10116">rats</span>
###xml 651 655 <span type="species:ncbi:10116">rats</span>
###xml 675 679 <span type="species:ncbi:10116">rats</span>
Next, we attempted to determine the molecular mechanism by which PPARbeta/delta activation inhibits NF-kappaB. Although it has been reported that PPARbeta/delta activation prevents LPS-induced degradation of inhibitor of kappaBalpha (IkappaBalpha), thus suppressing LPS-induced NF-kappaB in cardiomyocytes (31), we did not observe changes in the protein levels of this NF-kappaB inhibitor (data not shown) after GW501516 treatment. On the other hand, ERK1/2 activation leads to NF-kappaB activation in adipocytes (9). In agreement with this hypothesis, the adipose tissue of ZDF rats showed enhanced phospho-ERK1/2 levels in the adipose tissue of ZDF rats compared with lean rats (Fig. 6A). This observation supports a potential relationship between activation of ERK1/2 and NF-kappaB. To demonstrate the involvement of the ERK-MAPK cascade in LPS-induced NF-kappaB activation in adipocytes, we used U0126, a potent and specific ERK1/2 inhibitor, which binds to MEK, thereby inhibiting its catalytic activity and phosphorylation of ERK1/2. Cells exposed to LPS showed increased mRNA levels of both Mcp-1 (31-fold induction, P < 0.001) and IL-6 (fourfold induction, P < 0.05), whereas co-incubation with U0126 caused a 35% (P < 0.001) and 72% (P < 0.05) reduction in the LPS-mediated induction of these two genes, respectively (Fig. 6B and C). As a control, we verified that U0126 treatment inhibited LPS-induced ERK1/2 activation (Fig. 6D).
###end p 36
###begin p 37
###xml 215 216 204 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 209 216 198 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6<italic>E</italic></xref>
###xml 742 743 706 707 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 736 743 700 707 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6<italic>F</italic></xref>
###xml 643 647 <span type="species:ncbi:10090">mice</span>
###xml 655 659 <span type="species:ncbi:10090">mice</span>
###xml 730 734 <span type="species:ncbi:10090">mice</span>
Finally, we examined whether the PPARbeta/delta ligand prevented LPS-induced NF-kappaB activation by reducing ERK1/2 phosphorylation in adipocytes. Immunoblotting detection of total and phosphorylated ERK1/2 (Fig. 6E) revealed that LPS treatment activated this pathway, whereas in the presence of the PPARbeta/delta agonist, this pathway was blocked. These observations suggest that activation of this transcription factor prevents NF-kappaB activation by inhibiting ERK1/2 phosphorylation. To demonstrate that PPARbeta/delta regulates the ERK1/2 pathway, we explored the expression of this kinase in adipose tissue of the PPARbeta/delta-null mice. These mice showed enhanced phospho-ERK1/2 protein levels compared with wild-type mice (Fig. 6F), indicating that PPARbeta/delta regulates this pathway.
###end p 37
###begin title 38
DISCUSSION
###end title 38
###begin p 39
###xml 158 160 158 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r32">32</xref>
###xml 415 417 411 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r33">33</xref>
###xml 566 568 558 560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r34">34</xref>
###xml 781 783 766 768 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r35">35</xref>
###xml 902 904 883 885 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r36">36</xref>
###xml 983 985 960 962 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r26">26</xref>
###xml 1307 1309 1284 1286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r37">37</xref>
###xml 695 699 <span type="species:ncbi:10090">mice</span>
###xml 802 807 <span type="species:ncbi:9606">human</span>
###xml 1183 1191 <span type="species:ncbi:9606">patients</span>
###xml 1289 1294 <span type="species:ncbi:9606">human</span>
Obesity, insulin resistance, and type 2 diabetes are closely associated with low grade of chronic inflammation characterized by abnormal cytokine production (32). The adipocyte plays a crucial role in this process, because this cell is a source of cytokines (TNF-alpha, IL-6, and MCP-1), which are secreted as a result of the activation of several signaling cascades involved in obesity-induced insulin resistance (33). A number of studies have implicated chronic activation of the pro-inflammatory transcription factor NF-kappaB as one of these signaling pathways (34) that links inflammation with obesity and type-2 diabetes. For instance, overexpression of the NF-kappaB activator IKKbeta in mice results in increased inflammatory cytokine production and the onset of diabetes (35). Furthermore, in human adipose tissue, inhibition of NF-kappaB suppresses the release of pro-inflammatory cytokines (36). Activation of NF-kappaB can be achieved by either LPS or FFAs through TLR4 (26). Several studies have proposed that LPS participates in initiating the subclinical inflammation observed in obesity and type 2 diabetes. Thus, circulating LPS levels are higher in type 2 diabetic patients than in lean healthy subjects, and LPS stimulates the secretion of pro-inflammatory cytokines in human adipocytes (37).
###end p 39
###begin p 40
###xml 180 182 169 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r38">38</xref>
###xml 196 198 185 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r31">31</xref>
###xml 916 918 856 858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r34">34</xref>
###xml 962 963 898 899 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 1345 1346 1281 1282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 1950 1952 1853 1855 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r39">39</xref>
###xml 2167 2168 2056 2057 <italic xmlns:xlink="http://www.w3.org/1999/xlink">O</italic>
###xml 2240 2242 2129 2131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r40">40</xref>
###xml 1327 1332 <span type="species:ncbi:9606">human</span>
###xml 1767 1771 <span type="species:ncbi:10090">mice</span>
###xml 2044 2049 <span type="species:ncbi:9606">human</span>
###xml 2146 2150 <span type="species:ncbi:10090">mice</span>
Here, we demonstrate for the first time that PPARbeta/delta activation in adipocytes inhibits LPS-induced cytokine expression and secretion by preventing NF-kappaB activation. We (38) and others (31) have previously proposed that PPARbeta/delta activation inhibits NF-kappaB activation in cardiac cells either by promoting a protein-protein interaction between PPARbeta/delta and the p65 subunit of NF-kappaB or by increasing the expression levels of the NF-kappaB inhibitor IkappaBalpha. In adipocytes, we did not observe changes either in the PPARbeta/delta-p65 interaction (data not shown) or in IkappaBalpha protein levels after GW501516 treatment. These observations suggest that these mechanisms are not involved in the anti-inflammatory effects of this drug in adipocytes. In contrast, it has been previously reported that ERK1/2 activation is crucial for the induction of inflammatory changes in adipocytes (34) and leads to enhanced NF-kappaB activity (9). In agreement with this role of ERK1/2 in inflammation in adipocytes, we observed a reduction in the expression of pro-inflammatory cytokines in these cells when exposed to LPS in the presence of the MAPK pathway inhibitor, U0126. This finding is consistent with previous studies reporting reduced cytokine expression levels in the presence of this inhibitor in human adipocytes (9). These data demonstrate that ERK1/2 inhibition prevents NF-kappaB activation and the subsequent increase in cytokine expression. In addition, we demonstrate that PPARbeta/delta activation inhibits ERK1/2 phosphorylation, which is consistent with the reduction in NF-kappaB activation after GW501516 treatment. Furthermore, the increase in phospho-ERK1/2 levels observed in white adipose tissue from PPARbeta/delta-null mice is consistent with enhanced NF-kappaB activity. The involvement of PPARbeta/delta in ERK1/2 regulation has been previously reported in other cell types. In fact, Burdick et al. (39) recently reported that the PPARbeta/delta agonist GW0742 reduces phospho-ERK1/2 levels in human keratinocytes. In addition, phospho-ERK1/2 levels are higher in the skin of PPARbeta/delta-null mice treated with 12-O-tetradecanoylphorbol-13-acetate than in the skin of wild-type animals (40). Overall, these data confirm that PPARbeta/delta regulates phospho-ERK1/2 levels in several tissues. Additional studies are required to elucidate the molecular mechanism by which PPARbeta/delta controls ERK-1/2 activation.
###end p 40
###begin p 41
###xml 180 183 <span type="species:ncbi:10116">rat</span>
###xml 761 765 <span type="species:ncbi:10090">mice</span>
###xml 881 885 <span type="species:ncbi:10090">mice</span>
Here, we demonstrate a correlation between enhanced ERK1/2 phosphorylation and NF-kappaB activation in the white adipose tissue of a genetic model of obesity and diabetes, the ZDF rat. Given the low level of Pparbeta/delta in the white adipose tissue of these animals, we hypothesize that a decrease in the expression of this nuclear receptor is one of the underlying mechanisms of this correlation. On the basis of our data, we propose that in this animal model, PPARbeta/delta downregulation leads to enhanced ERK1/2 phosphorylation, which in turn activates NF-kappaB in white adipose tissue and, as a result, induces pro-inflammatory cytokine expression. This hypothesis is supported by the observation that white adipose tissue from the PPARbeta/delta-null mice shows increased phospho-ERK1/2 levels and NF-kappaB activity and higher expression of IL-6 compared with wild-type mice. Although further studies are required to demonstrate this relationship between PPARbeta/delta and NF-kappaB in white adipose tissue, our data provide further insight into the role of obesity-related insulin resistance and low-grade inflammation.
###end p 41
###begin p 42
In summary, on the basis of our findings in adipocytes, we propose that PPARbeta/delta activation prevents LPS-induced NF-kappaB activation via ERK1/2, thereby reducing the production of pro-inflammatory cytokines involved in the development of insulin resistance. This action of PPARbeta/delta may contribute to preventing obesity-induced insulin resistance.
###end p 42
###begin p 43
R.R.-C. has received a grant from the Fundacion Ramon Areces. T.C. has received a grant from the Spanish Ministerio de Educacion y Ciencia. X.P. has received a grant from the Spanish Ministerio de Educacion y Ciencia. This study has received funds from the Swiss National Science Foundation, Generalitat de Catalunya (SGROS-00833), Fundacion Ramon Areces, the Spanish Ministerio de Educacion y Ciencia (SAF2006-01475), Instituto de Salud Carlos III-RETIC RD06/0,015/ERDF, European Union ERDF funds, and the Fundacio Privada Catalana de Nutricio i Lipids.
###end p 43
###begin p 44
We thank the University of Barcelona's Language Advisory Service for its help.
###end p 44
###begin title 45
REFERENCES
###end title 45
###begin p 46
###xml 44 49 37 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdk-4</italic>
###xml 54 59 47 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cpt-I</italic>
###xml 209 210 201 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 221 222 213 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 344 348 336 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Aprt</italic>
###xml 428 429 418 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 440 441 430 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 457 458 447 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
The PPARbeta/delta agonist GW501516 induces Pdk-4 and Cpt-I expression in 3T3-L1 adipocytes. Differentiated adipocytes were incubated in the presence or in the absence of 0.5 mumol/l GW501516 for either 24 h (A) or 96 h (B). Total RNA was isolated and analyzed by RT-PCR. A representative autoradiogram and the quantification normalized to the Aprt mRNA levels are shown. Data are means +/- SD of five independent experiments. *P < 0.05, **P < 0.01, and ***P < 0.001 vs. control.
###end p 46
###begin p 47
###xml 399 404 386 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mcp-1</italic>
###xml 406 407 393 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 413 417 400 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-6</italic>
###xml 419 420 406 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 542 546 529 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Aprt</italic>
###xml 570 571 557 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 663 664 650 651 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 714 715 701 702 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 972 973 956 957 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 984 985 968 969 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1001 1002 985 986 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1025 1026 1009 1010 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1037 1038 1021 1022 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1054 1055 1038 1039 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
The PPARbeta/delta agonist GW501516 prevents LPS-induced expression and secretion of pro-inflammatory cytokines. When indicated, differentiated adipocytes were incubated with 0.5 mumol/l GW501516 for 96 h and subsequently exposed to 100 ng/ml LPS for 24 h in the presence or in the absence of GW501516 or 10 mumol/l NF-kappaB inhibitor parthenolide (PARTH). Effects of GW501516 on the expression of Mcp-1 (A) and IL-6 (B). Total RNA was isolated and analyzed by RT-PCR. A representative autoradiogram and the quantification normalized to the Aprt mRNA levels are shown. C: Effect of GW501516 on the secretion of IL-6 to the culture media, as determined by ELISA. D: Effect of GW501516 on the expression of SOCS-3. E: Analysis of STAT3 and phospho-STAT3 by immunoblotting of nuclear protein extracts from 3T3-L1 adipocytes treated with 100 ng/ml LPS for 3 h in the presence or in the absence of 0.5 mumol/l GW501516. Data are means +/- SD of five independent experiments. *P < 0.05, **P < 0.01, and ***P < 0.001 vs. control. #P < 0.05, ##P < 0.01, and ###P < 0.001 vs. LPS-exposed cells.
###end p 47
###begin p 48
###xml 289 290 277 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 332 334 320 322 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 500 501 484 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 515 516 499 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
The PPARbeta/delta agonist GW501516 prevents LPS-induced NF-kappaB activation in 3T3-L1 adipocytes. When indicated, differentiated adipocytes were incubated with 0.5 mumol/l GW501516 for 96 h and subsequently exposed to 100 ng/ml LPS for 1 h in the presence or in the absence of GW501516. A: Autoradiograph of EMSA performed with a 32P-labeled NF-kappaB nucleotide and crude nuclear protein extract (NE). Three specific complexes (I-III), based on competition with a molar excess of unlabeled probe (B), are shown. C: A supershift analysis performed by incubating NE with an antibody directed against the p65 subunit of NF-kappaB is also shown.
###end p 48
###begin p 49
###xml 147 156 136 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ppar&#946;/</italic>
###xml 163 164 145 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 167 172 149 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdk-4</italic>
###xml 174 175 156 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 182 186 164 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-6</italic>
###xml 188 189 170 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 356 360 338 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Aprt</italic>
###xml 440 441 420 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 450 451 430 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 493 495 473 475 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 656 661 636 641 <italic xmlns:xlink="http://www.w3.org/1999/xlink">right</italic>
###xml 858 859 831 832 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 901 903 874 876 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 1027 1032 996 1001 <italic xmlns:xlink="http://www.w3.org/1999/xlink">right</italic>
###xml 31 35 <span type="species:ncbi:10116">rats</span>
###xml 231 235 <span type="species:ncbi:10116">rats</span>
In white adipose tissue of ZDF rats, PPARbeta/delta expression is reduced, whereas NF-kappaB activity is increased. Analysis of the mRNA levels of Pparbeta/delta (A), Pdk-4 (B), and IL-6 (C) in white adipose tissue of lean and ZDF rats. Total RNA was isolated and analyzed by RT-PCR. A representative autoradiogram and the quantification normalized to the Aprt mRNA levels are shown. Data are means +/- SD of five independent experiments. *P < 0.05. D: Autoradiograph of EMSA performed with a 32P-labeled PPRE nucleotide and crude nuclear protein extract (NE). Three specific complexes (I-III), based on competition with a molar excess of unlabeled probe (right), are shown. An analysis performed by incubating NE with an antibody directed against PPARbeta/delta is also shown. This antibody does not shift the complex, but prevents its binding to the PPRE. E: Autoradiograph of EMSA performed with a 32P-labeled NF-kappaB nucleotide and NE. Two specific complexes, based on competition with a molar excess of unlabeled probe (right), are shown.
###end p 49
###begin p 50
###xml 121 130 110 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ppar&#946;/</italic>
###xml 137 138 119 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 141 146 123 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pdk-4</italic>
###xml 148 149 130 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 156 160 138 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Il-6</italic>
###xml 162 163 144 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 382 386 357 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Aprt</italic>
###xml 466 467 439 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 476 477 449 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 519 521 492 494 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 675 680 644 649 <italic xmlns:xlink="http://www.w3.org/1999/xlink">right</italic>
###xml 24 29 <span type="species:ncbi:10090">mouse</span>
###xml 235 240 <span type="species:ncbi:10090">mouse</span>
The PPARbeta/delta-null mouse shows increased NF-kappaB activity in white adipose tissue. Analysis of the mRNA levels of Pparbeta/delta (A), Pdk-4 (B), and Il-6 (C) in white adipose tissue of wild-type (wt) or PPARbeta/delta-null (ko) mouse white adipose tissue. Total RNA was isolated and analyzed by RT-PCR. A representative autoradiogram and the quantification normalized to the Aprt mRNA levels are shown. Data are means +/- SD of five independent experiments. *P < 0.05. D: Autoradiograph of EMSA performed with a 32P-labeled NF-kappaB nucleotide and crude nuclear protein extract (NE). One specific complex, based on competition with a molar excess of unlabeled probe (right), is shown.
###end p 50
###begin p 51
###xml 88 89 81 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 316 317 305 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 329 330 318 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 715 716 701 702 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 731 732 717 718 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 755 756 741 742 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 770 771 756 757 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 998 999 983 984 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1026 1027 1010 1011 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1030 1031 1014 1015 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 209 213 <span type="species:ncbi:10116">rats</span>
###xml 1069 1074 <span type="species:ncbi:10090">mouse</span>
PPARbeta/delta regulates ERK1/2 phosphorylation in adipocytes and white adipose tissue. A: Analysis of ERK and phospho-ERK by immunoblotting of total protein extracts from white adipose tissue of lean and ZDF rats. The MEK1/2 inhibitor U0126 blocks NF-kappaB activation by LPS. Analysis of the mRNA levels of Mcp-1 (B) and IL-6 (C) in 3T3-L1 adipocytes. Differentiated adipocytes were treated with 100 ng/ml LPS for 6 h in the presence or in the absence of 10 mumol/l of the MEK1/2 inhibitor U0126. Total RNA was isolated and analyzed by RT-PCR. A representative autoradiogram and the quantification normalized to the Aprt mRNA levels are shown. Data are expressed as means +/- SD of five independent experiments. *P < 0.05 and ***P < 0.001 vs. control; #P < 0.05 and ##P < 0.001 vs. LPS-exposed cells. Analysis of ERK and phospho-ERK by immunoblotting of total protein extracts from 3T3-L1 adipocytes treated with 100 ng/ml LPS for 10 min in the presence or in the absence of 10 mumol/l of U0126 (D) or 0.5 mumol/l GW501516 (E). F: Wild-type (wt) or PPARb/d-null (ko) mouse white adipose tissue.
###end p 51

